Mazildene: Full Drug Profile
Mazildene - General Information
Tricyclic anorexigenic agent unrelated to and less toxic than amphetamine, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter. [PubChem]
Pharmacology of Mazildene
Mazildene is a sympathomimetic amine, which is similar to an amphetamine. Mazildene stimulates the central nervous system (nerves and brain), which increases your heart rate and blood pressure and decreases your appetite. Sympathomimetic appetite suppressants are used in the short-term treatment of obesity. Their appetite-reducing effect tends to decrease after a few weeks. Because of this, these medicines are useful only during the first few weeks of a weight-loss program.
Mazildene for patients
Use caution when driving, operating machinery, or performing other hazardous activities. Mazindol may cause dizziness, blurred vision, or restlessness, and it may hide the symptoms of extreme tiredness. If you experience these effects, avoid hazardous activities. Mazindol is habit forming. You can become physically and psychologically dependent on this medication, and withdrawal effects may occur if you stop taking it suddenly after several weeks of continuous use. Talk to your doctor about stopping this medication gradually.
Mazildene Interactions
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. Changes in insulin and other diabetes drug therapies may be necessary during treatment with mazindol.Mazindol may reduce the effects of guanethidine (Ismelin). This could lead to an increase in blood pressure. Tell your doctor if you are taking guanethidine. Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). These drugs may decrease the effects of mazindol.
Mazildene Contraindications
Contraindicated in heart disease or high blood pressure, arteriosclerosis, and glaucoma.
Additional information about Mazildene
Mazildene Indication: Used in short-term (a few weeks) treatment of exogenous obesity in conjunction with a regimen of weight reduction based on caloric restriction, exercise, and behavior modification in patients with a body mass index of 30 kg of body weight per height in meters squared (kg/m2) or in patients with a body mass index of 27 kg/m2 in the presence of risk factors such as hypertension, diabetes, or hyperlipidemia. Mechanism Of Action: Although the mechanism of action of the sympathomimetics in the treatment of obesity is not fully known, these medications have pharmacological effects similar to those of amphetamines. Unlike other sympathomimetic appetite suppressants such as phentermine, mazindol is thought to inhibit the reuptake of norepinephrine rather than to cause its release. Drug Interactions: Acetophenazine Decreased anorexic effect, may increase psychotic symptomsChlorpromazine Decreased anorexic effect, may increase psychotic symptomsEthopropazine Decreased anorexic effect, may increase psychotic symptomsFluphenazine Decreased anorexic effect, may increase psychotic symptomsMethotrimeprazine Decreased anorexic effect, may increase psychotic symptomsMesoridazine Decreased anorexic effect, may increase psychotic symptomsMethdilazine Decreased anorexic effect, may increase psychotic symptomsPropericiazine Decreased anorexic effect, may increase psychotic symptomsPerphenazine Decreased anorexic effect, may increase psychotic symptomsProchlorperazine Decreased anorexic effect, may increase psychotic symptomsTrimeprazine Decreased anorexic effect, may increase psychotic symptomsTriflupromazine Decreased anorexic effect, may increase psychotic symptomsTrifluoperazine Decreased anorexic effect, may increase psychotic symptomsPromazine Decreased anorexic effect, may increase psychotic symptomsPromethazine Decreased anorexic effect, may increase psychotic symptomsPropiomazine Decreased anorexic effect, may increase psychotic symptomsThiethylperazine Decreased anorexic effect, may increase psychotic symptomsThioridazine Decreased anorexic effect, may increase psychotic symptomsVenlafaxine Risk of serotoninergic syndromeFluvoxamine Risk of serotoninergic syndromeFluoxetine Risk of serotoninergic syndromeGuanethidine The agent decreases the effect of guanethidineParoxetine Risk of serotoninergic syndromeIsocarboxazid Possible hypertensive crisisPhenelzine Possible hypertensive crisisRasagiline Possible hypertensive crisisTranylcypromine Possible hypertensive crisis Food Interactions: May be taken without regard to meals, but preferably 1 hour before a meal.If product causes GI problems, it can be taken during meals. Generic Name: Mazindol Synonyms: Not Available Drug Category: Adrenergic Uptake Inhibitors; Central Nervous System Stimulants; Dopamine Uptake Inhibitors Drug Type: Small Molecule; Approved Other Brand Names containing Mazindol: DEANo. 1605; Dimagrir; Magrilon; Mazanor; Mazildene; Mazindol [USAN-BAN-INN]; Mazindolum [INN-Latin]; Sanorex; Terenac; Teronac; Absorption: Not Available Toxicity (Overdose): Symptoms of a mazindol overdose include restlessness, tremor, rapid breathing, confusion, hallucinations, panic, aggressiveness, nausea, vomiting, diarrhea, an irregular heartbeat, and seizures. Protein Binding: Not Available Biotransformation: Hepatic. Half Life: 10-13 hours Dosage Forms of Mazildene: Not Available Chemical IUPAC Name: 5-(4-chlorophenyl)-2,3-dihydroimidazo[1,2-b]isoindol-5-ol Chemical Formula: C16H13ClN2O Mazindol on Wikipedia: https://en.wikipedia.org/wiki/Mazindol Organisms Affected: Humans and other mammals